STOCK TITAN

Casi Pharmaceuticals Inc (CASI) EPS by Year

CASI

Casi Pharmaceuticals Inc lost $2.59 per diluted share in fiscal year 2025. This represents a decrease of 1.2% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Casi Pharmaceuticals Inc has filed alongside them.

FY2025 annual
EPS (Diluted) -$2.59
YoY -1.2%
Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

CASI EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY22FY21FY20
EPS (Diluted)-$2.59-1.2%-$2.56-26.7%-$2.02+32.9%-$3.01-11.9%-$2.69+38.4%-$4.37

CASI EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'2510-KQ4'2410-KQ4'23Q4'22Q4'21
EPS (Diluted)N/AN/AN/AN/AN/A

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Casi Pharmaceuticals Inc financials

Frequently Asked Questions

What was Casi Pharmaceuticals Inc's diluted earnings per share in fiscal year 2025?

Casi Pharmaceuticals Inc lost $2.59 per diluted share in fiscal year 2025.

How fast is Casi Pharmaceuticals Inc's diluted earnings per share growing?

Casi Pharmaceuticals Inc (CASI) diluted earnings per share fell by 1.2% year over year, from -$2.56 to -$2.59 in fiscal year 2025.

How has Casi Pharmaceuticals Inc's diluted earnings per share changed over the years?

Across the 6 fiscal years this page covers, Casi Pharmaceuticals Inc (CASI) diluted earnings per share went from -$4.37 in fiscal year 2020 to -$2.59 in fiscal year 2025.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Casi Pharmaceuticals Inc (CASI) reported on that line in every period on record.